A Phase III, Randomised, Multicentre, Double-Blind, Comparative Study to Determine the Efficacy and Safety of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
Latest Information Update: 28 Jan 2020
Price :
$35 *
At a glance
- Drugs Nafithromycin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Wockhardt
- 28 Jan 2020 New trial record